透過您的圖書館登入
IP:3.142.255.18
  • 期刊
  • OpenAccess

Effects of Mitomycin-C on Retinal Pigment Epithelial Cells in Culture

Mitomycin-C對網膜色素性上皮細胞生長之影響

摘要


以藥物來控制增殖性玻璃體視網膜病變(PVR),多年來一直是學者們所研究的課題。我們在用抗癌藥物來抑制增殖性玻璃體視網膜病變時所常遭遇到的問題是:此藥是否有效?是否對網膜有毒性?以及藥物之投予是否方便可行?而以往所試驗之藥物均未臻理想。本篇用青光眼手術中廣泛使用之Mitomycin-C在視網膜方面做新的嘗試。我們將各種不同濃度之Mitomycin-C加入培養中之牛眼網膜色素性上皮細胞來試驗其抑制效果。結果顯示Mitomycin-C對網膜色素性上皮細胞之生長有明顯之抑制效果,且依其濃度大小而有不同。濃度即使僅有0.05微克/毫升也可在培養三天後達到-69%之抑制生長的效果。此濃度僅為最大安全劑量之6.25%而已。如此可謂Mitomycin-C是相當安全且有效。此外,只靠點藥水即可在玻璃體內達到此一濃度(0.05微克/毫升),而不像5-Fluorouracil那樣,需要反覆地眼球內注射。所以,基於其有效性,安全性及方便性,Mitomycin-C在增殖性玻璃體視網膜病變之預防上而言,可謂相當有其可行性。

關鍵字

無資料

並列摘要


Pharmacologic therapy of proliferative vitreoretinopathy (PVR) has been widely investigated and clinically used. The major problems encountered in antineoplastic agents as pharmacologic therapy of PVR are the potency of drugs, retinal toxicity and the delivery systems. Many antiproliferative agents have been tested but are still not satisfying enough. Mitomycin-C, one of the most important drugs in adjunctive therapy of glaucoma filtering surgery, has not been tested in the vitreoretinal field yet. We used the bovine retinal pigment epithelial cells (RPE) in culture to test the effect of Mitomycin-C. RPE were exposed to various concentrations of Mitomycin-C to see the inhibitory effect of Mitomycin-C on them. The result revealed that the Mitomycin-C inhibits the proliferation of RPE in culture in a dose- dependent manner. Concentration as low as 0.05ug/ml can achieve a significant inhibition (-69%) after 3 days of incubation. This is just 6.25% of the maximal nontoxic dose. Mitomycin-C is, therefore, potent and safe in the inhibition of RPE growth. Besides, this concentration (0.05ug/ml) can be acheived by topical eyedrops or sponge application only, instead of by repeated intraocular injections as used for the delivery of 5-fluorouracil. The efficacy, safety and feasibility of Mitomycin-C make it promising in the prevention of proliferative vitreoretinopathy.

延伸閱讀